Clinical trial NCT03429621: Effect of Simethicone on Reducing Bowel Interference During Tubal Resection
Official title: Effect of Simethicone on Reducing Bowel Interference During Minilaparotomy for Tubal Resection : a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sterility, Postpartum
Lead sponsor: Chiang Mai University
Sponsor class: OTHER
First posted: 2018-02-12
Enrollment: 120
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tubal ligation is an everyday procedure for permanent female sterilization. It is usually performed after a vaginal delivery. Minilaparotomy is generally performed by doing small incision at infraumbilical area. This minimal access surgery requires adequate operative field exposure. Bowel interference, which obscures visualization of the operative field has been recognized as one of the major obstacles during this procedure. We found problems while doing surgery in small space and one of them is bowel interferance which obscures vision. This could lead to prolonged operation and complications. Simethicone is an antifoaming agent that use in bowel preparation prior to various procedures including laparoscopy, colonoscopy, endoscopy, and open major abdominal operations. Simethicone is proven to break the bubble and reduce intraluminal gas. This effect could result in reduction of bowel dilatation that interfere with the proper identification of the adnexal area. Benefit of taking simethicone prior to do minilaparotomy for tubal resection has not been examined.

Objectives: To examine the effect of simethicone on reducing bowel interference during minilaparotomy for tubal resection.

Design: A randomized controlled trial in women, age 20-45 years, undergoing postpartum sterilization after vaginal delivery at Faculty of Medicine, Chiang Mai University hospital. The participants will be randomly assigned into one of two study groups: intervention (taking simethicone) and control (not taking simethicone). For the intervention group, each woman will take simethicone (80 mg) 2 tablet chewing with water 50 ml at 2-8 hours before surgery. Fasting at least 6 hours before surgery. For the control group, the women will receive the same standard perioperative care without taking simethicone. The primary outcome measure will be surgeon-rated operative difficulty score, which is a visual analog scale based on assess from exposure of to the operative field in visual analog scale by surgeon. The secondary outcome will be operative time and incidence of intraoperative and postoperative complications.


Eligibility criteria: Inclusion Criteria:

* Women requesting postpartum sterilization by minilaparotomic tubal resection after vaginal delivery at Faculty of Medicine, Chiang Mai University

Exclusion Criteria:

* Pre-pregnancy BMI \> 25 kg/m2
* Intraoperative general anesthesia or epidural anesthesia
* Previous abdominal surgery except for appendectomy
* Known bowel disorder including Crohn's disease, ulcerative colitis, previous bowel surgery

Primary outcomes:
measure: Operative difficulty score
timeFrame: At the end of operation (within 1 hour after the completion of the operation)
Secondary outcomes:
measure: Operation time (Total)
timeFrame: From the start of skin incision creation to the completion of skin closure (up to 2 hours)
measure: Operation time (Intraabdominal)
timeFrame: From first entering abdominal cavity to start closing the abdominal peritoneum (up to 2 hours)
Other outcomes:
Locations:
city: Chiang Mai
country: Thailand
facility: Department of OB-GYN, Faculty of Medicine, Chiang Mai University
Study officials:
affiliation: Faculty of Medicine, Chiang Mai University
name: Kittipat Charoenkwan, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References: